AGORACOM Investor Relations is pleased to bring you this Industry Report and how it can impact Biocurex (BOCX: OTCBB). An article in today’s New York Times reports that PSA Tests, used to screen for prostate cancer, saves few lives and leads to risky and unnecessary treatments for large numbers of men according to two studies.
According to the article, the findings confirm some longstanding concerns about the PSA tests and the wisdom of using it for widespread prostate cancer screening. The studies are continuing but so far the results are considered significant and the most definitive to date.
The article states: “Dr. Peter B. Bach, a physician and epidemiologist at Memorial Sloan-Kettering Cancer Center, says one way to think of the data is to suppose he has a PSA test today. It leads to a biopsy that reveals he has prostate cancer, and he is treated for it. There is a one in 50 chance that, in 2019 or later, he will be spared death from a cancer that would otherwise have killed him. And there is a 49 in 50 chance that he will have been treated unnecessarily for a cancer that was never a threat to his life.”
The article calls into question the use of the PSA test by saying: “As soon as the PSA test was introduced in 1987, it became a routine part of preventive health care for many men age 40 and older. Experts debated its value, but their views were largely based on less compelling data that often involved statistical modeling and inferences. Now, with the new data, cancer experts said men should carefully consider the possible risks and benefits of treatment before deciding to be screened.”
Both reports were published online Wednesday by The New England Journal of Medicine. One involved 182,000 men in seven European countries; the other, by the National Cancer Institute, involved nearly 77,000 men at 10 medical centers in the United States.
BioCurex’s patented RECAF technology has shown that it can detect many forms of cancer, including prostate cancer, with 90% accuracy through a simple non-invasive blood test. It is not known at this time the future of the PSA test, but the article does suggest the need for a much more effective test for prostate cancer that BioCurex is trying to address.
To read the article in its entirety simply click on the following link:
http://www.nytimes.com/2009/03/19/he...
AGORACOM is pleased to have brought you this Industry Report and how it can impact BioCurex. Feel free to comment on this article or any other facet of the business pertaining to BioCurex on this discussion forum.
.
AGORACOM Investor Relations
